At a glance
ClinicalIndex Comparison RecordN/ACompleted· 251 enrolled
Drug / intervention
T2769 +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of the Performance and Safety of T2769 Versus Vismed® Multi in the Treatment of Moderate to Severe Dry Eye Syndrome
In Brief
A clinical study evaluating T2769 and Vismed® Multi for Dry Eye. Completed, enrolled 251 participants across 1 site.
Detailed Summary
To demonstrate the non-inferiority of T2769 compared to Vismed® Multi in terms of total ocular surface staining (Oxford score) after 35 days of treatment. To evaluate the performance and safety of T2769 versus Vismed® Multi.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
202420252026
First PostedJul 2023
Enrollment StartOct 2023
Primary CompletionAug 2024
TodayJul 2026
First PostedJul 28, 2023
Enrollment StartOct 2, 2023
Primary CompletionAug 15, 2024
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 2.9 years ago
Interventions
T2769device
T2769: sodium hyaluronate, Trehalose, Naaga in a 12.5 mL ABAK® multi-dose bottle.
Vismed® Multidevice
Hyaluronic acid